Standardization Of Patient-Focused Core Clinical Outcomes Could Enable Labeling Comparisons
Executive Summary
US FDA’s Theresa Mullin envisions having a national catalog of standard core clinical outcomes assessment measures that could apply to every disease area.
You may also be interested in...
FDA Looking To Boost Transparency On How Patient Input Is Used In Drug Reviews
Sponsor concerns about commercial confidential information may be a sticking point in getting patient groups the desired data on when and how the FDA uses patient input in regulatory decision making.
New China Trial Design Rules Stress Patient Needs And Experience
China's Center for Drug Evaluation has finalized new guidelines that stipulate sponsors of randomized controlled clinical studies should more closely consider patient needs and experience when designing trials, including a consideration of likely future changes in standard therapies.
Patient-Focused Drug Development Grants May Be Program’s ‘Most Significant’ Accomplishment Since 2019
US FDA has issued five grants for development of standard core clinical outcome assessments and related endpoints that can be used across disease areas and may produce more reliable data for regulatory decision-making.